Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01339741|
Recruitment Status : Unknown
Verified April 2011 by Chulalongkorn University.
Recruitment status was: Recruiting
First Posted : April 21, 2011
Last Update Posted : April 21, 2011
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis Vulgaris Vitamin D Deficiency||Dietary Supplement: Vitamin D3 Drug: Placebo||Not Applicable|
While psoriasis is not a lethal disease, the disease itself can impact patients' quality of life. Nowadays there are several researches on vitamin D functions. Recently review article of vitamin D deficiency by Holick MF., stated that vitamin D can play a role in decreasing the risk of osteoporosis and other chronic diseases such as malignancy, autoimmune disease, infectious disease, cardiovascular disease, and psoriasis. Moreover, vitamin D effects on keratinocyte by decreasing abnormal cell proliferation, differentiation, apoptosis and controlling immunological process via the suppression of T-cell activation, regulation of cytokine secretion patterns, induction of regulatory T-cell, modulation of T-cell proliferation and interference with T-cell apoptosis.
Thus, our objective is to look for other alternative treatment, which may have less side effects and acceptable clinical outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||February 2012|
|Estimated Study Completion Date :||February 2012|
|Active Comparator: Vitamin D||
Dietary Supplement: Vitamin D3
Vitamin D3, oral supplement, 12 weeks
|Placebo Comparator: Placebo||
Placebo, oral route, 12 weeks
- Psoriasis Area and Severity Index (PASI Score) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlate with improved clinical outcome (PASI Score) of psoriasis vulgaris.
- Dermatologic Life Qualify Index (DLQI) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlates with better DLQI.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01339741
|Contact: Chotinij Lertphanichkul, M.D.||662-256-4000 ext email@example.com|
|Contact: Marisa Pongprutthipan, M.D.||662-256-4000 ext firstname.lastname@example.org|
|Chotinij Lertphanichkul, M.D.||Recruiting|
|Patumwan, Bangkok, Thailand, 10330|
|Contact: Chotinij Lertphanichkul, M.D. 662-256-4000 ext 4253 email@example.com|
|Contact: Marisa Pongprutthipan, M.D. 662-256-4000 ext 4253 firstname.lastname@example.org|
|Principal Investigator: Chotinij Lertphanichkul, M.D.|
|Principal Investigator:||Chotinij Lertphanichkul, M.D.||Chulalongkorn University|